Q1 2023 · 13F-HR
CHI Advisors LLCholdings as filed
Filed 2023-05-11 · accession 0001085146-23-002240
$376.7M
Reported value
24
Positions
2023-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 74349U108 | — | PROMETHEUS BIOSCIENCES INC | $100.3M | 26.6% | 934,135 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $79.8M | 21.2% | 3,001,835 | Common | SOLE |
| H9060V101 | — | VECTIVBIO HLDG AG | $44.7M | 11.9% | 5,255,484 | Common | SOLE |
| 230031106 | CGEM | CULLINAN ONCOLOGY INC | $34.3M | 9.10% | 3,349,460 | Common | SOLE |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $29.5M | 7.83% | 2,997,939 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $12.4M | 3.30% | 2,746,265 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $11.1M | 2.96% | 261,059 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $9.3M | 2.46% | 2,829,712 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $8.7M | 2.32% | 855,000 | Common | SOLE |
| 45790W108 | — | INOZYME PHARMA INC | $7.7M | 2.04% | 1,342,191 | Common | SOLE |
| 68217N105 | — | OMEGA THERAPEUTICS INC | $6.4M | 1.69% | 1,055,882 | Common | SOLE |
| 45175G108 | — | IKENA ONCOLOGY INC | $5.7M | 1.52% | 1,660,872 | Common | SOLE |
| 75120L100 | — | RALLYBIO CORP | $4.3M | 1.15% | 760,543 | Common | SOLE |
| 68570P200 | — | ORCHARD THERAPEUTICS PLC | $4.2M | 1.12% | 785,738 | Common | SOLE |
| 16961L106 | — | CHINOOK THERAPEUTICS INC | $3.1M | 0.83% | 135,000 | Common | SOLE |
| 74019P108 | — | PRECISION BIOSCIENCES INC | $2.6M | 0.69% | 3,469,820 | Common | SOLE |
| 690469101 | OVID | OVID THERAPEUTICS INC | $2.2M | 0.59% | 864,822 | Common | SOLE |
| 49372L100 | — | KEZAR LIFE SCIENCES INC | $2.2M | 0.57% | 689,451 | Common | SOLE |
| 35655L107 | — | FREELINE THERAPEUTICS HLDGS | $2.2M | 0.57% | 4,729,419 | Common | SOLE |
| 221015100 | CRVS | CORVUS PHARMACEUTICALS INC | $2.1M | 0.57% | 2,339,402 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $2.0M | 0.54% | 767,445 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $817,423 | 0.22% | 56,374 | Common | SOLE |
| 68236R103 | — | ONCORUS INC | $814,634 | 0.22% | 2,367,436 | Common | SOLE |
| 74349U108 | — | PROMETHEUS BIOSCIENCES INC | $108,125 | 0.03% | 25,000 | CALL | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.